From immunological and molecular biomarker perspective, predominance of CD8+ T cells among tumor infiltrating lymphocytes (TIL) at baseline and presence of ARID2 and NTRK1 mutations were associated with a favorable response to PD-1/PD-L1 ICI therapy in advanced MCC [114,120,268]. Here, CD8A is linked to neoplasm.